COMMUNIQUÉ DE PRESSE publié le 23/05/2024 à 16:30, il y a 5 mois 28 jours GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect JTC Team announces CEO Connect segment with GRI Bio's Marc Hertz, PhD, covering recent achievements and upcoming milestones. Virtual Investor platform offers more videos GRI Bio Virtual Investor CEO Connect JTC Team Communication Strategies
BRÈVE publiée le 25/04/2024 à 15:50, il y a 6 mois 25 jours Moleculin Biotech souligne le rôle de l'annamycine dans le traitement de la LMA dans le segment des investisseurs virtuels du JTC Essais Cliniques Opportunité D'investissement Biotechnologie Moléculaire Annamycine Traitement LMA
BRÈVE publiée le 25/04/2024 à 15:50, il y a 6 mois 25 jours Moleculin Biotech Emphasizes Annamycin's Role in AML Treatment in JTC Virtual Investor Segment Clinical Trials Investment Opportunity Moleculin Biotech Annamycin AML Treatment
COMMUNIQUÉ DE PRESSE publié le 25/04/2024 à 15:45, il y a 6 mois 25 jours Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team Moleculin CEO highlights Annamycin's differentiation in AML treatment landscape and investment opportunity. Positive interim data shared in 'What This Means' segment Investment Opportunity Clinical Trial Moleculin Biotech Annamycin AML Treatment
COMMUNIQUÉ DE PRESSE publié le 18/10/2023 à 16:00, il y a 1 année 1 mois JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023
Publié le 21/11/2024 à 06:58, il y a 6 heures 55 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 55 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 55 minutes Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 17 heures 46 minutes Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 18 heures 33 minutes Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Publié le 21/11/2024 à 13:30, il y a 23 minutes AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Publié le 21/11/2024 à 13:30, il y a 23 minutes Datametrex Secures Additional P.O. Approx $250K for IT Services
Publié le 21/11/2024 à 13:00, il y a 53 minutes Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Publié le 21/11/2024 à 13:00, il y a 53 minutes Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Publié le 21/11/2024 à 13:00, il y a 53 minutes Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Publié le 21/11/2024 à 13:41, il y a 12 minutes Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
Publié le 21/11/2024 à 12:35, il y a 1 heure 18 minutes audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Publié le 21/11/2024 à 12:15, il y a 1 heure 38 minutes Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
